Recombinant Von Hippel Lindau Tumor Suppressor (vHL)

HRCA1; RCA1; VHL1; Von Hippel-Lindau Syndrome

  • Recombinant Von Hippel Lindau Tumor Suppressor (vHL) Packages (Simulation)
  • Recombinant Von Hippel Lindau Tumor Suppressor (vHL) Packages (Simulation)
  • Recombinant Von Hippel Lindau Tumor Suppressor (vHL) Figure. Gene Sequencing (Extract)
  • RPJ769Hu01.jpg Figure. SDS-PAGE
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

SEQUENCE of the Recombinant Von Hippel Lindau Tumor Suppressor (vHL)

USAGE of the Recombinant Von Hippel Lindau Tumor Suppressor (vHL)

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

STORAGE of the Recombinant Von Hippel Lindau Tumor Suppressor (vHL)

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

STABILITY of the Recombinant Von Hippel Lindau Tumor Suppressor (vHL)

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Related products

Catalog No. Organism species: Homo sapiens (Human) Applications (RESEARCH USE ONLY!)
RPJ769Hu01 Recombinant Von Hippel Lindau Tumor Suppressor (vHL) Positive Control; Immunogen; SDS-PAGE; WB.
GUESTBOOK